Chinese biopharmaceutical company Innovent Biologics Inc (HKEX:01801) announced on Sunday that China's National Medical Products Administration (NMPA) has approved a new indication for the non-covalent (reversible) Bruton's tyrosine kinase (BTK) inhibitor, Jaypirca (pirtobrutinib), for the treatment of adult patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma (CLL/SLL) after at least one line of systemic therapy including a BTK inhibitor.
This approval is based on results from the international, multicentre, randomised, Phase 3 BRUIN CLL-321 study. BRUIN CLL-321 is the world's first randomised Phase 3 trial conducted in patients with CLL/SLL who had previously been treated with a covalent BTK inhibitor (cBTKi).
In October 2024, pirtobrutinib was approved in China as a monotherapy for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL) who have previously received at least two prior systemic therapies, including a BTK inhibitor.
Pirtobrutinib was approved by the US Food and Drug Administration (FDA) in January 2023 as a non-covalent BTK inhibitor.
Xcovery and EVERSANA partner for US commmercialisation of lung cancer drug Ensacove
Novartis secures European approval for remibrutinib in chronic spontaneous urticaria
Evofem signs exclusive deal to expand SOLOSEC distribution in sub-Saharan Africa
GSK secures US and EU fast-track designations for efimosfermin in MASH
AstraZeneca secures US approval for Saphnelo self-administration in lupus treatment
Abbott presents late-breaking clinical data on treating heart rhythm disorders
Novartis receives positive CHMP opinion for Itvisma in spinal muscular atrophy
Servier completes Day One Biopharmaceuticals acquisition
Cipla's AB-rated Ventolin HFA generic receives US FDA approval